SLS
Sellas Life Sciences Group Inc
12.00$
+4.0%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -1,028.6% | -1,162.4% | -460.0% | – | – | – | – | – | -548,263.2% | -342.4% | -2,380.9% | – | – | – | |
| – | – | – | – | – | – | 2.4% | 18.2% | 9.5% | – | – | – | – | – | 14,842.1% | 74.8% | 45.7% | – | – | – | |
| – | – | – | – | – | – | 68.4% | 101.7% | 57.8% | – | – | – | – | – | 30,421.1% | 13.3% | 172.6% | – | – | – | |
| – | – | – | – | – | – | 34.6% | -4.7% | 60.0% | – | – | – | – | – | 39,473.7% | 30.2% | 1,185.1% | – | – | – | |
| – | – | – | – | – | – | 5.2% | 100.9% | 42.8% | – | – | – | – | – | 294,210.5% | -100.2% | 564.1% | – | – | – | |
| – | – | – | – | – | – | 36.3% | 637.2% | 59.3% | – | – | – | – | – | 0.0% | 0.0% | 450.0% | – | – | – | |
| – | – | – | – | – | – | -4.3% | -484.0% | -59.3% | – | – | – | – | – | -236,842.1% | -59.2% | -450.0% | – | – | – | |
| – | – | – | – | – | – | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 2,053.0% | 1,846.4% | 276.5% | – | – | – | – | – | 2,007,052.6% | – | – | – | – | – | |
| – | – | – | – | – | – | -0.5% | 395.7% | -19.0% | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | 2,081.6% | 2,248.7% | 260.3% | – | – | – | – | – | 2,023,263.2% | 158.9% | 2,407.9% | – | – | – | |
| – | – | – | – | – | – | 1,048.8% | 602.3% | -259.0% | – | – | – | – | – | 1,475,000.0% | -183.5% | -423.0% | – | – | – | |
| – | – | – | – | – | – | -1,028.6% | -1,799.6% | -519.3% | – | – | – | – | – | -548,263.2% | -342.4% | -2,830.9% | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.